Table 1.
Baseline demographics and clinical characteristics of patients enrolled in the RISING study (n=327)
| Baseline value | |
|---|---|
| Age, year | 49.9 (12.0) |
| Gender, female | 267 (81.7)* |
| Disease duration, years | 8.2 (8.0) |
| Steinbrocker stage | |
| I | 32 (9.8)* |
| II | 114 (34.9)* |
| III | 105 (32.1)* |
| IV | 76 (23.2)* |
| Steinbrocker functional class | |
| 1 | 58 (17.7)* |
| 2 | 239 (73.1)* |
| 3 | 30 (9.2)* |
| 4 | 0 (0.0)* |
| Duration of methotrexate use, years | 2.7 (2.8) |
| Methotrexate dose, mg/week | 7.8 (1.7) |
| Glucocorticoid use | 223 (68.2)* |
| DAS28–CRP | 5.5 (4.9, 6.2)† |
| DAS28–ESRTJC, 68 joints | 6.2 (5.6, 6.8)†15.0 (10.0, 23.0)† |
| SJC, 66 joints | 12.0 (9.0, 17.0)† |
| CRP, mg/dl | 2.4 (1.2, 4.1)† |
| ESR, mm/h | 52 (35, 72)† |
| Patient pain VAS, mm | 54 (39, 72)† |
| Patient global VAS, mm | 54 (36, 72)† |
| Physician global VAS, mm | 64 (50, 78)† |
| TSS‡ | 35.5 (11.5, 73.4)† |
| Estimated yearly progression of TSS, point/year‡ | 6.1 (3.1, 11.4)† |
| HAQ | 1.1 (0.8, 1.6)† |
| RF value, IU/ml | 90 (36, 223)† |
| Anti-CCP antibodies value, IU/ml | ≥100 (28, ≥100)† |
| MMP-3 value, ng/ml | 219 (105, 419)† |
Data in baseline values are mean (SD),
number of patients (%), or
median (IQR).
Health assessment questionnaire (HAQ) score: scores can range from 0 (no difficulty) to 3 (unable to perform this activity).
Total modified Sharp score (TSS): scores can range from 0 to 390 (erosion score 0–230, joint space narrowing score 0–160), with high scores indicating more joint damage. Estimated yearly rate of progression of the TSS was based on the duration of disease and baseline TSS for every patient.
n=325.
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS 28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; MMP-3, matrix metalloproteinase 3; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.